‘Hyalrheuma,’ Hanmi Pharm’s arthritis treatment acquires FDA approval

Hanmi Pharm(CEO Sae-Chang Kwon & Jong-Soo Woo) announced on the 9^th that the company has acquired approval of ‘Hyalrheuma Inj,’ a self-developed arthritis treatment, from the U.S. FDA for the first time as a Korean company.

‘Hyalrheuma,’ a sodium hyaluronate injection developed using the company’s own fermentation technology, is a product injected directly on injured body parts.

Hanmi Pharm i...